[Adjuvant therapy with systemic JM-8 (carboplatin) in superficial bladder tumors. Results after 3 years of use].
We evaluated the 3-year efficacy of adjuvant treatment (after complete TUR) with systemic carboplatin in 34 patients with transitional cell bladder tumors in the superficial stages. Twenty-six patients with a one-year follow-up had a recurrence rate of 23%. Twenty-three patients with a two-year follow-up had a recurrence rate of 65.3%. Six patients with a three-year follow-up had a recurrence rate of 83.3%. Seventeen patients with tumor recurrence within three years had "minimal" recurrence. The course of the disease was very stable and remained unchanged in 4 cases that required no other treatment for one year. This treatment modality indicates a therapeutic effect; however, further studies and changes are warranted in order to obtain better results.
Gallo Rolania
F J
FJ
Servicio de Urología, Hospital Virgen Blanca, León, España.
Beneitez Alvarez
M
M
Roa Luzuriaga
M
M
de Blas Gómez
V
V
D000277:Adjuvants, Pharmaceutic / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011182:Postoperative Care; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery*
D000277:Adjuvants, Pharmaceutic; D016190:Carboplatin
Tratamiento adyuvante con JM-8 (carboplatino), por vía sistémica, en los tumores superficiales de vejiga. Resultados después de tres años de utilización.